Founders & Business Owners

At CG Results, we have long experience of working with founders and business leaders, especially in the fast-growing technology and healthcare sectors.

We partner with entrepreneurs to help them understand and explore their options, initiate investor targeting, to put forward their story in the most impactful way, and then to negotiate the best deal possible. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

If you’ve built a business over many years, your next deal may be the most important one you’ll ever do. You will need advisors who understand this intuitively, giving you clear and well-informed advice every step of the way. They’ll be advisors who appreciate that every deal, and every company, is unique.

In practical terms, you need a partner who can run the process, making sure you have the headspace to focus on the business itself. Our teams have the skills and expertise that mean the inevitable distraction of the M&A process is kept to a minimum. Business owners are often running a tight ship. Partnering with CG Results gives you the breadth of capability and senior level experience to allow you to achieve your objectives without damaging your business.

We empower our clients with the support and the advice to achieve the best result.

At Results, every deal is important to every single person in our firm. The deep relationships we have with our clients, underpins everything we do. Every journey is different and what we offer is a personal and committed approach where we’re beside you every step of the way. That emphasis on working together, means that we can make a big difference to the outcome and really drive value for everyone we work with.

Julie Langley

Head of Technology and Healthcare Advisory, UK & Europe

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Nov 2022
has been acquired by
An Interlock Equity-backed company
Oct 2022
has been acquired by
A Trill Impact-backed company
Jul 2022
has received investment from
Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF

CG Results. Great people creating great outcomes, together.

Latest Insights

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Reports
17th October 2022

MedTech Services – Drivers of growth and consolidation

Welcome to our MedTech Services Report. This sets out our views on the tailwinds driving growth and increased outsourcing, an overview of the MedTech CDMO and CRO market as well as the key drivers of consolidation in the sector. We hope that you enjoy this report and look forward to discussing the data and underlying […]